Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.
| Condition(s) | Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Study type | Interventional |
| Summary | RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target. |
| Who can participate | Inclusion Criteria: * Patients of either gender, ages 18-75 (including 18 and 75); * ECOG Performance Status: 0 or 1; * Confirmed as a solid tumor by histopathology or cytology; * At least one primary or metastatic lesion confirmed by conventional imagingļ¼ * During the screening period, tumor tissue samples (either archived previously or freshly biopsied) can be provided, with positive target expression of more than 1%; * Voluntarily participate in this study and sign a written informed consent form, agree to comply with the research procedures, and cooperate throughout the entire research process; * Women of childbearing potential must have a negative pregnancy test result. If the patient is of childbearing potential, she must agree to abstain from sexual activity or use highly effective |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Nanolattix Biotechnology Co., Ltd. |
| Locations | Wuxi, Jiangsu, China |
| Start date | 2026-01-29 |
| NCT ID | NCT07505069 |
| Official listing | https://clinicaltrials.gov/study/NCT07505069 |